glp-1 news today nov 2025 Therapies May Benefit MPN And MDS Patients GLP-1 Pipeline Update: November 2025

in 80% of these patients, T1DM predated the onset of epilepsy by a median time of 1.5 years (85)

rn ve hizmetlerin sunulmas ve tantlmas iin ibirlii yaplan ve/veya hizmet alnan i ortaklarmz, Acil yardm ars halinde konumunuzu tespit edecek olan yetkili mercilere, Dzenleyici ve denetleyici kurumlar ile mahkeme ve icra mdrlkleri gibi sair resmi kurumlara, kiisel verilerinizi talep etmeye yetkili olan dier kamu kurum veya kurulularna, Spor Ktphanesi ile ticari iliki iinde bulunan ve telefon numaranza sahip tzel kiilere, Gerekli grld durumlarda aktarlabilecektir

Safety Measurements Any adverse event during the course of the study was monitored and reported to the study staff at week 6 (visit 5) or week 12 (visit 8) in the clinic or directly to the principal investigator throughout the study

And since most modern research funding comes from governments, there's a desire to see as much direct economic benefit as possible, as quickly as possible, and we periodically face calls to eliminate research about seemingly useless knowledge

Taking into account the above-mentioned considerations on cost and safety aspects, oral small molecule agonists stimulating endogenous GLP-1 secretion by intestinal L-cells may offer a promising alternative for developing new treatments for Type 2 diabetes and obesity

Key Definitions GLP-1 microdosing refers to using doses below the validated initiation levels studied in large randomized clinical trials of GLP-1 receptor agonists such as semaglutide and tirzepatide